Treatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies

Contemporary combined therapies that include the use of all-trans retinoic acid (ATRA) and arsenic compounds have reduced relapse rates from ~50 to <10% in acute promyelocytic leukemia (APL) patients, however relapse treatment remains controversial. Treatment outcomes in relapsed patients with AP...

Descripción completa

Detalles Bibliográficos
Autores principales: LU, JIN, HUANG, XIAOJUN, BAO, LI, JIANG, HAO, ZHU, HONGHU, JIANG, BIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861585/
https://www.ncbi.nlm.nih.gov/pubmed/24348844
http://dx.doi.org/10.3892/ol.2013.1643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861585/
https://www.ncbi.nlm.nih.gov/pubmed/24348844
http://dx.doi.org/10.3892/ol.2013.1643

Ejemplares similares